Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Interim Management Statement

2 Oct 2014 07:00

RNS Number : 2305T
Xaar PLC
02 October 2014
 



2 October 2014

 

Xaar plc

 

Interim Management Statement

Xaar plc ("Xaar", "the Group" or "the Company"), the digital inkjet printing technology Group headquartered in Cambridge, UK, is providing an Interim Management Statement covering trading from 1 July 2014.

 

As stated in the Interim Results announcement on 28 August 2014, demand for Xaar's products from the ceramic tile market softened during the third quarter of the year as a result of a slowdown in construction activity in China. The Company's exposure to China is significant, as almost half of the world's ceramic tile output is reported as manufactured and consumed in China. Revenue into the global ceramic tile market represented around two thirds of the Group's sales in 2013.

Monitoring of the ceramic tile market in China has indicated a further decline in activity resulting in excess manufacturing capacity being idled. As a consequence, forecast orders from Xaar's OEMs in this market for the remainder of the year have further reduced, such that the Board now expects total revenue for 2014 to be 5%-10% below the bottom of the previously announced range of £115-125 million.

Although visibility into 2015 remains low, based on all of the information currently available to the Group concerning the ceramic tile market in China, the Group is now planning to take action to reduce costs in anticipation of total Group revenue for 2015 being below £100 million.

Action will be taken immediately to reduce costs in line with the reduced expectation for sales in 2015. This is expected to result in a 15% reduction in operating expenditures, and potentially a total reduction in headcount (subject to consultation) of approximately 20% of the current global workforce of around 800 employees.

The cost reductions aim to achieve a reasonable level of financial operating performance in 2015, whilst ensuring that Xaar can fulfil its key strategic objectives.

Ian Dinwoodie, Chief Executive, commented, "We are highly disappointed to have to make this level of cost reduction given the progress achieved over the last four years. Our exposure to the ceramic tile market in China, which delivered such strong growth over the last few years, is now driving a reduction in our sales. This change re-emphasises the need for Xaar's revenues over time to become more broadly spread across multiple markets and applications. Our competitive position remains strong through our established market leading products, recently announced offerings, and planned future launches. Development efforts on both our Bulk technology and our Thin Film technology provide an excellent basis for our future success as the digitalisation of industrial and commercial printing continues".

A conference call for analysts will take place at 8.00am this morning. The conference call can be accessed by dialling +44 (0)203 139 4830 and using pin code 80375705#.

 

Contacts 

Xaar plc

Ian Dinwoodie, Chief Executive Officer

01223-423663

Alex Bevis, Finance Director

www.xaar.com

Tulchan Communications

Tom Buchanan

Christian Cowley

Victoria Huxster

 

020-7353-4200

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDGXSGBGSB
Date   Source Headline
1st Jul 20221:10 pmRNSTotal Voting Rights
21st Jun 20225:20 pmRNSDirector Declaration - Additional Directorship
1st Jun 202210:22 amRNSTotal Voting Rights
25th May 20221:57 pmRNSResult of AGM
3rd May 20225:20 pmRNSTotal Voting Rights
7th Apr 20226:31 pmRNSPDMR Shareholding
7th Apr 20222:50 pmRNSGrant of Options and Deferred Bonus Share Awards
1st Apr 202210:48 amRNSTotal Voting Rights
29th Mar 20227:00 amRNS2021 Full Year Results
28th Mar 202210:44 amRNSHolding(s) in Company
21st Mar 202212:37 pmRNSNotice of 2021 Preliminary Results
3rd Mar 20227:00 amRNSAcquisition of Megnajet
1st Mar 20225:29 pmRNSTotal Voting Rights
1st Feb 20225:00 pmRNSTotal Voting Rights
18th Jan 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSTrading Update
4th Jan 20222:39 pmRNSBlock listing Interim Review
4th Jan 20222:37 pmRNSTotal Voting Rights
10th Dec 20214:23 pmRNSGrant of Awards - Replacement
6th Dec 202112:25 pmRNSHolding(s) in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
5th Nov 202110:30 amRNSGrant of Sharesave Options
1st Nov 20214:11 pmRNSCompletion of Divestment of Xaar 3D
1st Nov 20211:56 pmRNSTotal Voting Rights
29th Oct 20214:41 pmRNSSecond Price Monitoring Extn
29th Oct 20214:36 pmRNSPrice Monitoring Extension
25th Oct 202110:38 amRNSResult of General Meeting
15th Oct 202111:50 amRNSGrant of Options and Deferred Bonus Share Awards
14th Oct 20218:44 amRNSBlock Listing Application
13th Oct 20212:52 pmRNSHolding(s) in Company
6th Oct 20212:43 pmRNSPublication of Circular and Notice of GM
6th Oct 20217:00 amRNSProposed divestment of Xaar 3D
1st Oct 202111:59 amRNSTotal Voting Rights
14th Sep 20217:00 amRNS2021 Interim Results
3rd Sep 202112:59 pmRNSNotice of 2021 Interim Results
2nd Sep 20213:40 pmRNSTotal Voting Rights
2nd Aug 20215:02 pmRNSTotal Voting Rights
22nd Jul 20217:00 amRNSTrading Update
12th Jul 20217:00 amRNSAcquisition of FFEI
1st Jul 20213:20 pmRNSBlock listing Interim Review
1st Jul 202110:51 amRNSTotal Voting Rights
22nd Jun 20215:37 pmRNSHolding(s) in Company
22nd Jun 202111:44 amRNSHolding(s) in Company
16th Jun 20211:17 pmRNSResult of AGM
1st Jun 202110:10 amRNSTotal Voting Rights
17th May 20219:27 amRNSHolding(s) in Company
12th May 202110:15 amRNSHolding(s) in Company
4th May 20213:01 pmRNSTotal Voting Rights
30th Apr 20216:23 pmRNSAnnual Financial Report
27th Apr 20217:00 amRNS2020 FULL YEAR RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.